What type of study is this?

This is a Pre-Registered Trial study.

What question did this study set out to answer?

To assess the long-term outcomes of imetelstat in patients with lower-risk myelodysplastic syndromes.

December 8, 2025Blood

Long-term outcomes from the randomized, double-blind, placebo (PBO)-controlled, phase 3 imerge trial of imetelstat (IME) for lower-risk myelodysplastic syndromes (LR-MDS)

View Full Paper

Ask AI

Bookmark

Authors

VSValeria SantiniUniversity of Florence MSMichael R. SavonaVanderbilt University MDMaría Díez‐CampeloCleveland Clinic

Discussion

Member takes

Implication

Randomized trial shows treatment improves progression-free survival in patients with lower-risk myelodysplastic syndromes, highlighting the importance of subgroup analyses.

Key Points

To assess the long-term outcomes of imetelstat in patients with lower-risk myelodysplastic syndromes.
Phase 3, randomized, double-blind, placebo-controlled trial
Patients with RBC transfusion-dependent lower-risk myelodysplastic syndromes randomized to treatment or placebo
Endpoints included overall survival, progression-free survival, and safety.
Median overall survival was 47.8 months for imetelstat compared to 44.8 months for placebo.
Progression-free survival favored imetelstat, with an overall median of 47.6 months.
Safety profile remained consistent with no new safety signals reported.

Cite This Study

Santini et al. (2025) studied this question.

synapsesocial.com/papers/69362f6e4fa91c937236e0b7 https://doi.org/10.1182/blood-2025-2074

View Full Paper

Ask AI

Bookmark

Implication

Randomized trial shows treatment improves progression-free survival in patients with lower-risk myelodysplastic syndromes, highlighting the importance of subgroup analyses.

Long-term outcomes from the randomized, double-blind, placebo (PBO)-controlled, phase 3 imerge trial of imetelstat (IME) for lower-risk myelodysplastic syndromes (LR-MDS)

Discussion

Member takes

Implication

Key Points

Cite This Study

Long-term outcomes from the randomized, double-blind, placebo (PBO)-controlled, phase 3 imerge trial of imetelstat (IME) for lower-risk myelodysplastic syndromes (LR-MDS)

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider